Osanni Bio gets $190M to build ophthalmology and cardiology pipeline
San Francisco biotech Osanni Bio, looking to build out a suite of ophthalmology- and cardiology-focused
Osanni Bio is a San Francisco-based biotechnology company building a pipeline of therapeutics for ophthalmology and cardiology indications. The company raised $190M in 2026 to advance its portfolio of small-molecule and biologic candidates addressing high-prevalence vision and cardiovascular diseases.
San Francisco biotech Osanni Bio, looking to build out a suite of ophthalmology- and cardiology-focused
Founder and Chief Executive Officer